Skip to main content

Table 3 Hazard ratios of death within five years according to LY6D expression in Cohorts I and II

From: Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer

 

Cohort I

Cohort II

 

Univariable

Multivariable

 

Univariable

Multivariable

 

n (events)

HR(95% CI)

HR(95% CI)

n (events)

HR(95% CI)

HR(95% CI)

Age

 Continuous

100 (45)

1.06 (1.03–1.09)

1.06 (1.02–1.09)

260 (82)

1.05 (1.02–1.08)

1.04 (1.01–1.08)

Gender

 Male

74 (33)

1.00

180 (59)

1.00

 Female

26 (12)

1.15 (0.60–2.24)

80 (23)

0.88 (0.54–1.42)

Stage

 pTa

45 (7)

1.00

1.00

114 (16)

1.00

1.00

 pT1

21 (14)

5.42 (2.18–13.47)

2.10 (0.69–6.37)

81 (24)

2.58 (1.37–4.87)

1.65 (0.80–3.57)

  ≥ pT2

34 (24)

7.98 (3.42–18.60)

3.39 (1.06–10.91)

65 (42)

8.14 (4.55–14.55)

3.47 (1.45–8.30)

Grade

 Low

47 (8)

1.00

1.00

126 (18)

1.00

1.00

 High

53 (37)

6.35 (2.95–13.71)

2.26 (0.76–6.68)

134 (64)

4.47 (2.64–7.54)

1.44 (0.65–3.20)

Histology

 Classic

   

209 (48)

1.00

1.00

 Squamous

   

14 (10)

6.12 (3.08–12.15)

2.39 (1.11–5.14)

 Other variant

   

37 (24)

4.44 (2.71–7.27)

2.04 (1.16–3.59)

LY6D expression

 Negative (0)

37 (24)

1.00

1.00

93 (38)

1.00

1.00

 Positive (1–2)

63 (21)

0.50 (0.25–0.81)

0.86 (0.47–1.60)

167 (44)

0.58 (0.37–0.89)

0.78 (0.48–1.25)

  1. Only cases in which LY6D could be assessed were included in all analyses
  2. Apart from LY6D expression, only factors with significant hazard ratios in the univariable analyses were
  3. included in the multivariable analyses.0 = Negative LY6D expression, 1 = ≤ 50% positive LY6D expression, 2 = > 50% LY6D expression